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INTRODUCTION
State of the Discipline
Pediatric SCT programs have smaller patient volumes com-
pared to adult programs. This makes innovative, well-organized,
and inclusive study designs directed at compelling questions par-
amount. COG has pursued this agenda by addressing three goals:
(1) To improve efﬁcacy of SCT in the treatment of childhood
cancers through a better understanding and application of alloge-
nicity (graft vs. tumor or graft vs. leukemia [GVL]) as a thera-
peutic tool; (2) to improve the safety of SCT by addressing major
causes of transplant-related morbidity and mortality; and (3) to
optimize design, collaborate in development and assure timely
completion of SCT-related therapy and research protocols devel-
oped through the COG disease and Cancer Control committees.
COG-focused studies, including ASCT0521, ASCT0431, and
CTN 0501 are described below. These SCT studies showcase
design approaches that are the foundation of SCT research within
COG. The ﬁrst design strategy is the utilization of novel bench
and research observations to design trials targeted at improving
outcomes and changing SCT practice. Speciﬁcally, ASCT0521
tested a novel treatment of idiopathic pneumonia syndrome
(IPS) using a TNF antagonist, based on speciﬁc data generated
by COG investigators showing the presence of TNF in bron-
cheoalveolar lavage samples of patients with IPS. ASCT0431
was built on built on lab data from COG investigators indicating
that mTOR pathway inhibitors (e.g., sirolimus) have an anti-ALL
effect; this trial was the ﬁrst test of an agent used to control both
relapse and GVHD after SCT and is deﬁning the current baseline
for the role of GVHD and minimal residual disease (MRD) in
modern pediatric transplant studies. The ASCT0631 study was
built on a phase 2 study conducted by the Pediatric Blood and
Marrow Transplant Consortium (PBMTC) that showed promising
outcome using G-CSF-stimulated bone marrow (G-BM) [1] prod-
ucts from related donors, resulting in a phase 3 study. CTN 0501
was a collaboration between the Bone Marrow Transplant Clinical
Trials Network (BMT-CTN) and COG, testing the efﬁcacy of
single versus double umbilical cord blood unit transplant.
The second study development area has included disease-
speciﬁc studies with a signiﬁcant transplant emphasis, or for
which SCT is a major question. These studies for which a major
question is directed toward a transplant intervention include sev-
eral approaches involving AML and neuroblastoma (AAML0531,
AAML1031, and ANBL0532 studies). In the case of transplant
for neuroblastoma, the SCT and Neuroblastoma Committees
developed the ANBL00P1 tandem transplant pilot trial that devel-
oped the SCT regimen which was then used as the experimental
arm of the ANBL0532 single versus tandem SCT study. Current-
ly, the implementation of using busulfan/melphalan condition
regimen in two studies, ANBL09P1 and ANBL12P1 is being
pursued.
Reducing transplant-associated toxicity remains a major
challenge. Two open studies are being pursued, including the
ACCL1031, a randomized trial of topical Caphosol for mucositis
and ACCL0934, a randomized trial of prophylactic levoﬂoxacin.
Two additional studies are expected to open within the next
3 months: a randomized trial of caspofungin versus ﬂuconazole
in SCT and a trial of testing the ability of chlorhexidine gluconate
The role of SCT in pediatric oncology has continued to evolve
with the introduction of new therapeutic agents and immunological
insights into cancer. COG has focused its efforts on the study of
hematopoietic stem cell transplantation in the treatment of pediatric
malignancies in several major multi-institutional Phase II and Phase
III studies. These studies include addressing the impact of alloge-
nicity in ALL (ASCT0431), and establishing autologous stem cell
transplant as the standard of care in neuroblastoma. Reducing trans-
plant-associated toxicity was addressed in the ASCT0521 study,
where the TNFa inhibitor etanercept was tested for the treatment
of idiopathic pneumonia syndrome. Impact of cell dose was ex-
plored in the single versus tandem umbilical cord blood study CTN-
0501, in close collaboration with the BMT-CTN. Pediatr Blood
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(CHG) to reduce central venous line infections.
Major Recent Findings
Soluble Tumor Necrosis Factor Receptor: Etanercept for
the Treatment of Acute Non-Infectious Pulmonary Dysfunction
(Idiopathic Pneumonia Syndrome) Following Allogeneic Stem
Cell Transplantation. Pulmonary complications signiﬁcantly con-
tribute to the mortality associated with allogeneic SCT and are
being addressed in a new study (ASCT0521). In approximately
50% of cases, no infectious organisms are identiﬁed in the lungs
of affected patients. Idiopathic pneumonia syndrome (IPS) refers
to a diffuse, non-infectious lung injury that occurs acutely post
transplant. Diagnostic criteria for IPS include clinical signs and
symptoms of pneumonia, non-lobar radiographic inﬁltrates, ab-
normal pulmonary function, and the absence of infectious organ-
isms in the lower respiratory tract. Clinically, IPS is associated
with a rapid progression to respiratory failure, and mortality
rates of 50–75%. Historically, corticosteroids plus supportive
care measures, including supplemental oxygen, have provided
the primary treatment for patients with IPS.
Given the mortality rates associated with this disorder, newer
treatment modalities are required to improve survival. Recent
evidence indicates that immunologic mechanisms resulting in
activation of proinﬂammatory cytokines may contribute to the
development of IPS. Both murine models of lung injury and
recent human clinical trials have shown that pro-inﬂammatory
cytokines, including TNFa are elevated in the BAL ﬂuid of sub-
jects with IPS post allogeneic transplant. Etanercept is a dimeric
protein consisting of two soluble TNF receptors fused to the Fc
portion of a human IgG1 molecule. Clinical trials using etanercept
have now been conducted in patients with rheumatoid arthritis,
Crohn’s disease, sepsis syndrome and congestive heart failure.
Pharmacokinetic data and toxicity proﬁles have been generated
from these clinical trials. A pilot study for patients with IPS post
allogeneic transplant was recently completed and showed re-
sponse rates were favorable with minimal toxicity reported [2].
ASCT0521 was an open label, non-randomized trial investi-
gating the use of etanercept for the treatment of IPS occurring
after allogeneic HCT. It was designed to evaluate the response of
IPS to 8 doses of etanercept given over 24 days. The primary
objective was to determine the response rate to etanercept plus
corticosteroids in patients with IPS. Response was deﬁned strictly
as both (a) survival to Day 28, plus (b) the complete discontinua-
tion of supplemental oxygen support by Day 28 of study. Histori-
cally, 30% of subjects with IPS have responded successfully to
treatment with steroids alone using this deﬁnition of response,
so a response rate of 55% was targeted in this phase 2 setting.
This target was met and the study was closed prior to completing
enrollment, which proceeded according to projections, having
successfully met the response endpoint prior to accruing
40 patients. Analysis is ongoing.
Samples were collected for biology studies as well. Pre-
liminary studies have shown that a number of pro-inﬂammatory
cytokines and chemokines may be innately involved in the devel-
opment of IPS [3,4]. Signiﬁcant roles for LPS, TNFa, and CCR2/
MCP-1 in the development of IPS have now been reported in
both preclinical and clinical models. We collected BAL ﬂuid
and plasma for analysis of a panel of inﬂammatory cytokines
(IL-1, IL-2, IL-6, TNFa, sTNFR, TGF-b), components of the
lipopolysaccharide (LPS) activation system (LPS, LPB, and
CD14), and pro-inﬂammatory chemokines including CCR2/
MCP-1, and RANTES. Analysis of these samples is ongoing.
The biologic data provided from this study should ultimately
help elucidate the underlying mechanism of IPS and lead to
predictive models for future trials.
A Randomized Trial of Sirolimus-Based Graft versus Host
Disease Prophylaxis after Hematopoietic Stem Cell Transplanta-
tion in Relapsed ALL. Based upon preclinical data showing
signiﬁcant single-agent activity of the mTOR inhibitor sirolimus
(rapamycin) against human ALL blasts in ALL xenograft models
[5–10], combined with a promising pilot study conducted at
four COG centers [11], a phase 3 randomized trial ASCT0431
was initiated. This trial tested the hypothesis that the addition of
sirolimus to a GVHD prophylaxis regimen of tacrolimus/metho-
trexate would decrease relapse of high risk ALL after allogeneic
SCT. Trial eligibility included selected very high-risk CR1
patients (Phþ patients with persistent MRD, hypodiploid
(<44 chromosomes) and primary induction failure patients), and
children with high risk relapsed ALL in CR2. The trial accrual
was accruing at target for most of the open period of the trial and
ran without major issues.
In May of 2011 the trial was closed when an interim analysis
showed that survival reached a planned futility threshold. The
analysis showed that further accrual from 145 to the planned
259 patients was unlikely to result in an improvement in survival
by 16%, the primary aim of the study. Although the primary
hypothesis did not prove to be correct, many key ﬁndings were
noted and presented at the 2011 American Society of Hematology
Meeting [12]. The key observations were as follows: (1) Overall
and Event-Free survival was similar between the two arms, with
no difference in relapse rates, the ﬁnding which triggered the
futility stopping rule; (2) patients enrolled on the sirolimus arm
had a statistically signiﬁcant decrease in rates of grade II–IV acute
GVHD (49.1% vs. 31.5%, P ¼ 0.03); (3) no change was noted
between the two arms in rates of chronic GHVD; and (4) trans-
plant related mortality was quite low (14% overall with no differ-
ence between the arms). Subanalyses showed several important
observations that clarify these ﬁndings. First, the most important
association with decreased relapse was the presence of any level
of acute GVHD. Rates of relapse in patients with grade II–IV
acute were 20%, while those without GVHD exceeded 50%.
This observation was signiﬁcant in both study arms. The tight
correlation between GVHD and a graft-versus-leukemia effect
leads to the supposition that any direct anti-leukemia beneﬁt
from sirolimus was offset by suppression of the graft-versus-leu-
kemia effect. Multivariate analysis conﬁrmed that relapse rates in
patients with acute GVHD were 20% of those with no acute
GVHD. Coupled with the fact that TRM is only slightly affected
by signiﬁcant GVHD (relative risk 1.5), this means that in modern
pediatric HCT, mild-moderate GVHD does more good than
harm. In addition future studies planned must be mindful of
interventions that have could impact on GVL.
Another key observation from this study came from correla-
tion of outcomes with ﬂow cytometry-based minimal residual
disease assessment pre- and post-HCT. Detection of any disease
pre-HCT by our reference ﬂow laboratory (Michael Borowitz,
Johns Hopkins) more than tripled patients’ risk of relapse. This
suggests that MRDþ patients pre-HCT are at very high risk, and
should be a primary target for future interventional studies that
are targeted at reducing MRD pre-HCT or preventing relapse after
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HCT. Correlative studies currently underway include correlation
of chimerism and deep sequencing MRD with outcomes, assess-
ment of the acquisition of ALL blast resistance to sirolimus,
assessment of immunogenicity of blasts, and correlation of bio-
markers to rates of development of acute and chronic GVHD.
In addition to these studies conducted by the SCT Committee,
several other cooperative studies were successfully completed
by our committee together with other COG Committees or with
another cooperative group, the BMT-CTN. One of these was
ANBL0532, the singe versus tandem SCT study for patients
with high-risk neuroblastoma, which recently completed accrual.
Similarly, we partnered with the Neuroblastoma Disease Commit-
tee on A3973, a successfully completed trial testing the impact of
peripheral blood stem cell purging on outcome after single SCT
for neuroblastoma [13].
Multi-center, Open Label, Randomized trial Comparing Single
versus Double Umbilical Cord Blood (UCB) Transplantation in
Pediatric Patients with High Risk Leukemia and Myelodysplasia.
Cell dose is a major determinant of leukemia-free survival in a
number of BMT studies. In nearly every large single center or
registry analysis of outcomes after umbilical cord blood (UCB)
transplantation, cell dose is identiﬁed as an important factor inﬂu-
encing the incidence and rate of hematopoietic recovery, risk of
transplant-related mortality and probability of survival. Pilot data
suggest that infusion of two partially HLA-matched UCB units,
which always augments the graft cell dose, is safe and may
improve neutrophil recovery and survival. To determine whether
the infusion of two UCB units enhances survival, a multi-center,
open-label, randomized trial was designed (CTN-0501) by the
BMT-CTN; COG SCT participated in an intergroup fashion to
maximize accrual to this important trial. As adequate single UCB
units can be identiﬁed for >80% of pediatric recipients (in con-
trast to <30% for adults), the study was open only to pediatric
patients, which made access to COG SCT centers key to this
study’s success. The study population was restricted to patients
with high-risk hematologic malignancy, the most common indica-
tion of UCB transplantation in children.
The objective was to determine the efﬁcacy of using two
UCB units versus one UCB unit, with the primary endpoint being
1-year survival. There were several secondary endpoints, includ-
ing evaluating the incidence and time to engraftment subjects
receiving a single UCB unit as compared to two UCB units and
evaluating the impact of two UCB units on immune reconstitution
on chimerism, infections, and immune reconstitution. CTN-0501
was designed as a Phase 3, randomized, open-label, multi-center,
prospective study of single UCB transplantation versus double
UCB transplantation in pediatric patients with hematologic ma-
lignancies. The target sample size was 110 patients per study arm
(total of 220 patients). Because of the study’s pediatric HCT
focus, it proceeded as a major collaborative interaction between
two major stakeholders in transplant research, COG and the BMT-
CTN. The study has met accrual, and half of the subjects were
enrolled through the COG, demonstrating the ability of two co-
operative groups to collaborate on these kinds of multicenter studies.
Futute Trials and Challenges
A Randomized Phase II Study Comparing Two Different
Conditioning Regimens Prior to Allogeneic Hematopoietic Cell
Transplantation (HCT) for Children with Juvenile
Myelomonocytic Leukemia (JMML). ASCT1221 is a randomized
phase II study comparing two different conditioning regimens
prior to allogeneic HCT for children with JMML. JMML is an
uncommon disease occurring exclusively in young children and,
with rare exceptions, cures have only been achieved following
SCT. We have hypothesized that the primary mechanism by
which SCT results in long-term disease-free survival in some
patients with JMML is due to the provision of a source of allor-
eactive graft-versus leukemia (GVL) activity. As such, we further
hypothesized that the myeloablative preparative regimen prior to
SCT plays little role per se in the long-term disease-control of
patients with JMML, provided that it is sufﬁcient to achieve donor
cell engraftment and adequate transfer of alloreactive cells.
The trial’s primary objective is to determine the preferred
regimen for future trials in patients with JMML based on the
observed Day 100 treatment-related mortality (TRM) and event-
free survival (EFS) rates. Eligible patients will have JMML, and
most patients will have genotypically conﬁrmed disease, the test-
ing of which will be performed at a CLIA/CAP-certiﬁed central
laboratory funded by an approved National Cancer Institute Bio-
marker, Imaging, Quality of Life, and Cost Effectiveness Analy-
ses Funding Program (BISQFP) grant. Patients with Noonan
Syndrome are excluded. Patients will be randomized to one of
two myeloablative conditioning regimens within strata deﬁned by
donor type and PTPN11 mutation status. Our hypothesis is that
patients randomized to receive a busulfan-ﬂudarabine (BU-FLU)
conditioning regimen will have less TRM and equivalent
EFS when compared to a busulfan-cyclophosphamide-melphalan
(BU-CY-MEL) conditioning regimen, a regimen that has emerged
as the standard of care in Europe [14]. Pre-transplant therapy
is left to the discretion of the treating institution. Patients will
be followed for a minimum of 18 months, and the frequency of
research samples will coincide with the schedule utilized by the
European EWOG-MDS JMML protocol to enhance possible col-
laborations in this rare disease.
A total of 108 patients are estimated to be needed to answer
the primary question of the study, and the enrollment period is
expected to last 5 years. Secondary objectives include determin-
ing the 18-month relapse incidence (RI) and the graft failure rates
following the two different myeloablative conditioning regimens.
Clinical exploratory objectives include determining the rates of
severe toxicities and GVHD post-SCT between the two condition-
ing regimens, as well as creating a JMML-speciﬁc pre-SCT index
to allow better risk-stratiﬁcation of future patients. Correlative
biologic studies will determine the feasibility of assessing post-
transplant disease burden by donor chimerism measurements
and mutant allele burden. We will also attempt to validate gene
expression classiﬁers using RNA-based or methylation-based
arrays in patients with JMML that may predict relapse, and will
comprehensively assess genetic and biochemical alterations
amongst patients with JMML who are treated on this transplant
protocol.
The COG SCT committee works in partnership with two other
clinical trials groups, the BMT CTN and the PBMTC. The
PBMTC is 1 of 19 Core Centers of the BMT CTN, working to
develop pediatric-focused trials and facilitate pediatric enrollment
onto BMT CTN trials. This collaboration of the NCI/NHLBI
sponsored BMT CTN and COG has resulted in rapid patient accrual
(220þ patients) on clinical trials; this type of collaboration is a
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good example of bringing together different consortia to accrue
sufﬁcient numbers of subjects to answer key questions.
In terms of future efforts that exploit this collaboration with
the PBMTC, the COG SCT Committee plans to develop and
complete innovative early phase/pilot HCT trials in oncology,
which can then move to larger phase III trials in the BMT CTN
or COG. These efforts to improving survival in pediatric patients
with high-risk leukemia undergoing allogeneic HCT, include four
key hypotheses as follows.
Increasing BM CD34þ cell dose (by G-CSF primed BM) or
cord blood cell dose (1 unit vs. 2 units) improves survival. Studies
to test this hypothesis are now complete. MRD detection pre- and
post-transplant will (a) guide the choice of intensity of preparative
regimens that optimize survival and decrease late effects, (b)
identify very high risk patients pre-transplant who can/should
receive novel approaches pre-, during-, and post-transplant, and
(c) identify patients at high risk post-transplant, prompting early
interventions to prevent relapse. Here, the detailed analysis of
the MRD and chimerism data from ASCT0431 will be key in
developing approaches to prevent relapse in ALL. Use of pre- and
post-transplant MRD will be key measures of risk and the foun-
dation of future transplant approaches to these diseases.
Reduced toxicity regimens can increase cure of selected
patients with leukemia by reducing TRM. This is being
approached the development of a new preparative regimen
approach into the AAML1031 trial. Busulfan/ﬂudarabine has
been shown to have less risk of TRM compared to busulfan/
cyclophosphamide in adult studies. This approach is not being
piloted in AML patients through COG. A similar agent, treosul-
fan, shows promise of even less TRM. In addition, therapeutic
monitoring, essential to the use of busulfan, is not needed for
children receiving treosulfan. The PBMTC is piloting this agent
in the study PBMTC ONC1101. If treosulfan looks promising, it
can be compared with either busulfan/ﬂudarabine or busulfan/
cyclophosphamide in a future COG study.
Post-transplant relapse can be decreased by use of targeted
agents and novel immunological interventions. The ﬁrst COG
SCT Committee attempt to use a targeted agent was sirolimus
post-transplant, as outlined previously. Future approaches need to
be more speciﬁc and not interfere with graft versus leukemia
effects. Several potential approaches are being used. First, we
are working with the relapsed ALL group to develop a bridging
trial that uses blinatumomab to decrease MRD pre-transplant in
high risk relapsed ALL patients. Other approaches may use this
agent post-transplant to prevent relapse as well. Testing a CD19
antibody conjugated to pseudomonas endotoxin is planned in the
pre-transplant setting. Approaches using chimeric antigen recep-
tor-T-cells (CAR-T-cells) against CD19 developed at the Univer-
sity of Pennsylvania [15–19] will moved to limited center studies
in the next few years, with the ultimate goal of moving to multi-
center studies in COG as soon as possible.
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